|
End-of-day quote
London S.E.
|
||
| - GBX | - |
|
| 04:27am | GSK gets Japan approval for prefilled Shingrix vaccine | AN |
| 03:31am | GSK Gets Japan Approval for Prefilled Shingrix Syringe | MT |
| Market Cap | 72.27B 97.76B 84.08B 79.33B 135B 9,347B 136B 945B 364B 4,741B 367B 359B 15,058B | P/E 2026 * |
13.8x | P/E 2027 * | 11.3x |
|---|---|---|---|---|---|
| Enterprise Value | 92.99B 126B 108B 102B 174B 12,027B 175B 1,216B 468B 6,100B 472B 462B 19,376B | EV / Sales 2026 * |
2.74x | EV / Sales 2027 * | 2.54x |
| Free-Float |
92.75% | Yield 2026 * |
3.86% | Yield 2027 * | 4.16% |
Last Transcript : GlaxoSmithKline plc
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | 52 | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
James Ford
CMP | Compliance Officer | - | 2018-07-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | 52 | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 67 | 2019-08-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.24% | -2.75% | +49.45% | +89.36% | 1,002B | |
| -0.10% | -4.22% | +51.70% | +63.94% | 644B | |
| +0.70% | -2.93% | +19.35% | +69.47% | 443B | |
| -0.63% | -3.09% | +29.84% | +36.08% | 343B | |
| +0.43% | -14.61% | +11.32% | +26.98% | 262B | |
| +0.93% | -3.19% | -1.31% | +11.96% | 245B | |
| -2.19% | -13.81% | +37.44% | +46.26% | 212B | |
| -0.90% | -5.06% | -18.47% | -58.14% | 199B | |
| -0.44% | -4.16% | +25.75% | +88.12% | 181B | |
| Average | -0.06% | -5.00% | +22.78% | +41.56% | 392.19B | |
| Weighted average by Cap. | +0.06% | -4.24% | +32.07% | +56.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.95B 45.93B 39.5B 37.27B 63.46B 4,391B 64.04B 444B 171B 2,227B 172B 169B 7,074B | 35.49B 48.01B 41.29B 38.96B 66.35B 4,590B 66.95B 464B 179B 2,328B 180B 176B 7,395B |
| Net income | 5.38B 7.28B 6.26B 5.91B 10.06B 696B 10.15B 70.34B 27.07B 353B 27.33B 26.74B 1,121B | 6.37B 8.62B 7.42B 7B 11.92B 824B 12.02B 83.33B 32.07B 418B 32.38B 31.67B 1,328B |
| Net Debt | 20.72B 28.03B 24.11B 22.75B 38.74B 2,680B 39.09B 271B 104B 1,359B 105B 103B 4,318B | 17.98B 24.33B 20.92B 19.74B 33.62B 2,326B 33.93B 235B 90.49B 1,180B 91.36B 89.37B 3,748B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Select your edition
All financial news and data tailored to specific country editions
